文献速递新发突发、热带与寄生虫病

非流行区间日疟与卵形疟复发及伯氨喹效果

Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
PubMed 文献 · Clin Infect Dis · 2022-01-01

瑞典1995-2019年全国回顾性研究纳入3254例疟疾,分析972例间日疟与251例卵形疟。间日疟首次复发率9.3%高于卵形疟4.1%(P<.01);未用伯氨喹时间日疟复发风险33.3%高于卵形疟10.0%(HR 3.5,95%CI 1.0-12.0)。伯氨喹降低间日疟复发(7.1% vs 33.3%,HR 0.2,95%CI .1-.3),对卵形疟未达统计学显著(2.8% vs 10.0%,HR 0.3,95%CI .1-1.1)。

要点

  • 间日疟复发风险显著高于卵形疟,两者复发特征不同。
  • 伯氨喹可有效预防间日疟复发。
  • 卵形疟复发少,伯氨喹支持证据有限。

核心结论

  • 卵形疟复发风险明显低于间日疟,提示两虫种复发特征不同。
  • 伯氨喹能有效预防间日疟复发。
  • 卵形疟复发例数少,伯氨喹预防复发的证据仍有限。

研究设计与样本

  • 瑞典1995-2019年全国性回顾性研究,复习3254例疟疾病历。
  • 选取全部间日疟972例和卵形疟251例进行分析。

主要发现

  • 间日疟首次复发80/857(9.3%),卵形疟9/220(4.1%),P<.01。
  • 未用伯氨喹时间日疟复发20/60(33.3%),卵形疟3/30(10.0%),HR 3.5(95%CI 1.0-12.0)。
  • 间日疟用伯氨喹复发7.1% vs 未用33.3%,HR 0.2(95%CI .1-.3)。
  • 卵形疟用伯氨喹复发2.8% vs 未用10.0%,HR 0.3(95%CI .1-1.1),未达统计学显著。

临床怎么用

  • 对间日疟应按指南使用伯氨喹以降低复发风险。
  • 卵形疟复发率较低,伯氨喹使用需权衡有限证据。
  • 非流行区接诊输入性疟疾时应关注间日疟和卵形疟的复发监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of primaquine in preventing Plasmodium vivax relapses from dormant stages is well established. For Plasmodium ovale, the relapse characteristics and the use of primaquine is not as well studied. We set to evaluate the relapsing properties of these 2 species, in relation to primaquine use among imported malaria cases in a nonendemic setting. METHODS: We performed a nationwide retrospective study of malaria diagnosed in Sweden 1995-2019, by reviewing medical records of 3254 cases. All episodes of P. vivax (n = 972) and P. ovale (n = 251) were selected for analysis. RESULTS: First time relapses were reported in 80/857 (9.3%) P. vivax and 9/220 (4.1%) P. ovale episodes, respectively (P < .01). Without primaquine, the risk for relapse was higher in P. vivax, 20/60 (33.3%), compared to 3/30 (10.0%) in P. ovale (hazard ratio [HR] 3.5, 95% confidence interval [CI] 1.0-12.0). In P. vivax, patients prescribed primaquine had a reduced risk of relapse compared to episodes without relapse preventing treatment, 7.1% vs 33.3% (HR 0.2, 95% CI .1-.3). In P. ovale, the effect of primaquine on the risk of relapse did not reach statistical significance, with relapses seen in 2.8% of the episodes compared to 10.0% in patients not receiving relapse preventing treatment (HR 0.3, 95% CI .1-1.1). CONCLUSIONS: The risk of relapse was considerably lower in P. ovale than in P. vivax infections indicating different relapsing features between the two species. Primaquine was effective in preventing P. vivax relapse. In P. ovale, relapse episodes were few, and the supportive evidence for primaquine remains limited.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wångdahl A, Sondén K, Wyss K, et al. Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. Clin Infect Dis. 2022. PMID: 34216464. doi:10.1093/cid/ciab610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。